^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Tyrosine kinase inhibitor

    Related drugs:
    3d
    Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    Cdactin-O (CBM588) • zanzalintinib (XL092)
    8d
    CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (clinicaltrials.gov)
    P3, N=240, Recruiting, EyePoint Pharmaceuticals, Inc.
    Trial initiation date
    |
    Eylea (aflibercept intravitreal)
    9d
    VEGFR-2 blocker induces pulmonary vascular disease in rats with CRISPR-edited human non-deficient G6PD polymorphism: role of 3D genomic modifications and DNA methylation. (PubMed, Br J Pharmacol)
    This suggests that our findings reflect a heretofore unknown connection between G6PD polymorphisms and the 3D genomic organization that controls VEGFR blocker-induced expression of DNA/histone demethylases. Potential effects include up-regulation of genes encoding proteins, which evoke cell migration and inflammation within the lungs and contribute to the pathogenesis of PVD.
    Preclinical • Journal
    |
    KDR (Kinase insert domain receptor) • IL1B (Interleukin 1, beta)
    |
    semaxanib (SU5416)
    20d
    Global knockout of melanoma differentiation-associated protein 5 protects mice from chronic hypoxia/SU5416-induced pulmonary hypertension. (PubMed, Am J Physiol Lung Cell Mol Physiol)
    Knockdown of MDA5 in macrophage-like cells reduced the type I interferon gene signature. Our data suggest a protective effect of whole-body MDA5 knockout in mice, which may be due to reduced immune dysregulation.
    Preclinical • Journal
    |
    ITGAM (Integrin, alpha M) • IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    semaxanib (SU5416)
    22d
    ctDNA-guided dynamic monitoring for befotertinib combined with radiotherapy in oligometastatic non-small cell lung cancer with EGFR mutations: a single-arm, multicenter, exploratory study (ChiCTR2600120895)
    P2, N=84, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
    New P2 trial • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Semena (befotertinib)
    22d
    Study on the incidence of venous thromboembolism in patients with locally advanced or metastatic NSCLC harboring EGFR-sensitive mutations treated with befotertinib with or without rivaroxaban (ChiCTR2600119885)
    P4, N=1382, National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College; National Cancer Center/Cancer Hospital,Ch
    New P4 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Semena (befotertinib)
    27d
    Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma (clinicaltrials.gov)
    P2, N=20, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • zanzalintinib (XL092)
    1m
    A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma (clinicaltrials.gov)
    P2, N=16, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    zanzalintinib (XL092)
    1m
    EYP-1901-303: COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (2025-523937-25-00)
    P2/3, N=37, Not yet recruiting, Eyepoint Pharmaceuticals Inc.
    New P2/3 trial
    |
    Eylea (aflibercept intravitreal)
    1m
    Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study (clinicaltrials.gov)
    P3, N=850, Not yet recruiting, Ocular Therapeutix, Inc.
    New P3 trial
    1m
    Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, OHSU Knight Cancer Institute
    New P2 trial
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • zanzalintinib (XL092)
    1m
    Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma (clinicaltrials.gov)
    P2, N=20, Suspended, M.D. Anderson Cancer Center | Not yet recruiting --> Suspended
    Trial suspension
    |
    Keytruda (pembrolizumab) • zanzalintinib (XL092)